Vertex Pharmaceuticals

YTD

ALL

Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About VRTX

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.

CEO

Reshma Kewalramani

CEOReshma Kewalramani

Employees

6,100

Employees6,100

Headquarters

Boston, Massachusetts

HeadquartersBoston, Massachusetts

Founded

1989

Founded1989

Employees

6,100

Employees6,100

VRTX Key Statistics

Market cap

125.72B

Market cap125.72B

Price-Earnings ratio

-222.15

Price-Earnings ratio-222.15

Dividend yield

—

Dividend yield—

Average volume

2.00M

Average volume2.00M

High today

$492.23

High today$492.23

Low today

$485.08

Low today$485.08

Open price

$492.23

Open price$492.23

Volume

1.21M

Volume1.21M

52 Week high

$519.88

52 Week high$519.88

52 Week low

$377.85

52 Week low$377.85

VRTX News

Simply Wall St 5d

April 2025's Stocks That May Be Priced Below Their Estimated Value

As the U.S. stock market navigates a period of heightened volatility, with major indexes experiencing significant fluctuations amid tariff discussions and econo...

Simply Wall St 5d

Exploring 3 High Growth Tech Stocks In The US Market

The United States market has experienced a notable uplift, climbing by 5.8% over the past week and showing a 4.8% increase over the last year, with earnings pro...

Analyst ratings

57%

of 35 ratings

Buy

57.1%

Hold

37.1%

Sell

5.7%